Novartis AG, a Swiss multinational pharmaceutical company based in Basel, Switzerland, revealed that its new heart failure drug, Entresto, has been recommended for approval in Europe by the European Medicines Agency's review body.
The decision made by Committee for Medicinal Products for Human Use has send Entresto more closer to get approval for heart failure and reduced ejection fraction (HFrEF) patients across Europe by year-end, the company said.
Entresto, which is also known as LCZ696, is the first new drug in decades that claims to help patients whose lives are in danger because their hearts cannot pump blood efficiently. The drug is expected to be one of the biggest new drugs launched in 2015.
Novartis drug Odomzo has received go-ahead signal from the US Food and Drug Administration. The drug will treat advanced basal cell carcinoma skin cancer that has returned after surgery or radiation therapy.
Basal cell carcinoma is the abnormal, uncontrolled growth that happens in the skin's basal cells present in the deepest layer of the epidermis. This type of cancer is responsible for over 80% of non-melanoma skin cancers.
The drug is an oral, selective smoothened inhibitor, which handles hedgehog signalling pathway. It is said that the FDA has approved the drug after seeing the results of the clinical trials. In the trials it was noticed that 58% of those given the drug have witnessed partial shrinkage or complete disappearance of tumor.
This week, the Food and Drug Administration approved a new heart failure drug by Novartis and this led to excitement in the medical community. According to many, the drug is reliable "blockbuster" and "breakthrough”, which will help save millions of lives.
According to Clyde Yancy, a cardiologist and chief of the division of cardiology at Northwestern University Feinberg School of Medicine, some patients are already contacting him to request access to the new drug.
According to reports, the Food and Drug Administration has approved a drug from Novartis for treatment of heart failure. The drug helped reduce death and severe conditions caused by the problem. The drug named Entresto has already led to a lot of excitement.
Almost a year ago, announcement regarding the results of a clinical trial was made. The results showed a 20% decrease in the risk of fatality from cardiovascular diseases or hospitalization for severe heart problem.
On Monday night in Manhattan federal court, the government filed papers in which it stated that Novartis AG should pay $3.35 billion in damages and civil fines because the company has used wrong measures to strengthen its sales of two drugs covered in Medicare and Medicaid.
The government said that the company should pay that much amount under the federal False Claims Act for alleged improper reimbursements for Exjade and Myfortic. The former drug is used by patients who require blood transfusions and the latter one for patients with kidney transplants.
On Monday, Swiss drug company Novartis AG said that it has been shown in the new trial results that Cosentyx or secukinumab was much better than placebo. The trial also showed continual efficacy over one year in patients suffering from psoriatic arthritis.
The one year results of the Phase III FUTURE 2 Study have been published in the medical journal Lancet. Novartis said that secukinumab showed fast onset of action and was considerably superior to placebo, when it comes to working on signs and symptoms of psoriatic arthritis or PsA and efficacy was sustained over one year.
On Thursday, Novartis, a Swiss-based pharmaceutical company, reported an enormous jump in first-quarter net profit.
The company's net profit rose to $13.005 billion from $2.968 billion in the year-ago quarter. Profit was boosted by a $10.8 billion gain from transactions with GlaxoSmithKline PLC and Eli Lilly and Co.
Novartis' animal health business was sold to American global pharmaceutical company Lilly. Novartis also bought cancer drugs from British multinational healthcare company GSK and sold its non-flu vaccines business.
Both the companies combined their consumer health care businesses. These deals helped the company to focus on three core businesses, which include pharmaceuticals, generic drugs and eye care.
Novartis AG, one of the world's leading cancer R&D companies, has shifted its focus on using the body's immune system to battle tumors. As many as 22 oncology drugs from Novartis are currently available in the market to treat cancers, ranging from breast cancer to leukemia. The company is also developing 25 other treatments for cancer.
A research group having expertise in the field of immuno-oncology has been recently launched by the drug manufacturer. The Swiss company has hired an internationally known cancer vaccine authority, Dr. Glenn Dranoff, to lead the group. The aim is to focus on three distinct therapeutic areas and figure out how they can be combined with existing cancer drugs.
Sandoz, a Novartis company, announced that the United States Food and Drug Administration (FDA) has approved its Glatopa, which the first generic alternative version for Teva Pharmaceutical's multiple sclerosis treatment Copaxone. According to reports, Glatopa has been approved as treatment for multiple sclerosis.
After the approval, now the subsidiary of Novartis could market the drug. According to reports, Sandoz developed the new drug in partnership with Momenta Pharmaceuticals, a pharmaceutical company based in Massachusetts. The drug will be helpful in treating patients with relapsing forms of multiple sclerosis (MS). Some patients with severe MS lose the ability to walk independently or at all.
New Delhi - Drug major Novartis has been slapped with a Rs 300-crore penalty by drug regulator NPPA for overcharging consumers on sale of Voveran, its best-selling painkiller medicine.
The Swiss drugmaker, which did not confirm the quantum of the total penalty by the the National Pharmaceutical Pricing Authority (NPPA), said the notice is "erroneous and entirely misconceived".
"Novartis has received a notice from NPPA and will duly respond to the same. Novartis believes the show cause notice to be erroneous and entirely misconceived and Novartis will challenge both the basis of the demand as well as the entire quantum of the demand," Novartis India Ltd today said in a filing to the BSE.
The Indian Medical Association has welcomes a landmark ruling by the Supreme Court of India, in which it did not grant a patent to Novartis for a blockbuster drug after a long legal battle.
Swiss drug maker, Novartis faced a defeat in a patent issue as India's apex court dismissed its patent bid for a blockbuster cancer drug. The company condemned the decision by the Supreme Court of India to dismiss its patent application. The decision by the Supreme Court came after legal battle for seven years by the company to gain a patent protection for an updated version of leukemia drug Glivec in the country.
Swiss drug maker, Novartis faced a defeat in a patent issue as India's apex court dismissed its patent bid for a blockbuster cancer drug.
The company condemned the decision by the Supreme Court of India to dismiss its patent application. The decision by the Supreme Court came after legal battle for seven years by the company to gain a patent protection for an updated version of leukemia drug Glivec in the country.
New Delhi, April 1 : Health experts welcomed the landmark ruling of the Supreme Court Monday, rejecting Swiss drugmaker Novartis AG's attempt to patent its cancer drug, saying the dictum would ensure that patients get access to cheaper life-saving drugs.
"This is a landmark judgment. This will have a long-term and wide impact, as the generic version makes it more affordable for the poor. Now the prices of life-saving drugs will be reduced from Rs. 1,60,000 per month to just Rs. 6,000," Y. K. Sapru, of the Mumbai-based Cancer Patients Aid Association told IANS over phone.
New Delhi, April 1 : The Supreme Court Monday dismissed Swiss pharmaceutical chain Novartis AG's petition seeking patent protection for its anti-cancer drug, Glivec (Imatinib mesylate).
The apex court bench of Justices Aftab Alam and Ranjana Prakash Desai dismissed with cost Novartis' plea challenging the Intellectual Property Appellate Board's decision declining the plea for patent of the drug that is used in the treatment of chronic myeloid leukaemia and malignant gastrointestinal stromal tumours.
Swiss-firm Novartis AG has said that it is reducing its stake in Novartis India in order to meet Securities Exchange Board of India (SEBI) regulations on the minimum public shareholding in all listed firms.
Novartis AG, which is based in Basel, Switzerland, is planning to reduce its stake in the Indian unit through the stock exchange mechanism, Novartis India said in a filing with the Bombay Stock Exchange (BSE). Novartis AG had a stake of 76.42 stake in Novartis India as of September 30, 2012.
Global pharmaceutical major, Novartis AG has approached the Supreme Court of India in order to ensure the patent protection of its cancer drug, Glivec in the country.
Many believe that the outcome of this high profile patent battle will determine the prospects of several global pharmaceuticals companies in India who are distressed about the Indian government’s move to promote generic versions of medicines.
As per a report, Novartis, a pharmaceutical company in India was being claimed to be planning to quit from stock exchange. The company opened on Monday with a rise of 12% and there was a further increase by 2% amounting to Rs 864.95 on BSE.
An all new vaccine has been put against meningitis B that apparently will be scheduled for the next year with Novartis claiming that the shot has been tested in case of human beings.
Novartis’ drug, Bexsero has been bestowed by health experts who state that the jab will aid in a sharp decline in the number of children death due to the disease.
Pharmaceutical firm Novartis India has declared its first quarter financial results for the fiscal year 2010-11. The company has informed that there has been a marginal decline in its net profit for the June quarter of this year against the similar period last year.
Novartis India has posted a net profit of Rs 31.53 crore for this quarter which was reported to be Rs 31.76 crore for the corresponding quarter last year.
However, there has been a hike in company's net sales during the April-June period of fiscal year 2010 against last year.
One of the leading pharmaceutical companies, Array BioPharma has signed a deal with the Novartis AG.
The deal is a licensing deal for the experimental cancer drug candidates of Array BioPharma. The Swiss drug maker Novartis AG is also ready for the license arrangement with the America Inc.
The financial aspects of the contract have been published. Array has to pay the Swiss company $45 million as upfront payments and $422 million in milestones.
However, the share prices of the American pharmaceutical company have gone up by 30% just after the announcement of the deal.